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ABSTRACT
Mutations in the RNA-binding protein FUS cause
amyotrophic lateral sclerosis (ALS), a devastat-
ing neurodegenerative disease. FUS plays a role
in numerous aspects of RNA metabolism, includ-
ing mRNA splicing. However, the impact of ALS-
causative mutations on splicing has not been fully
characterized, as most disease models have been
based on overexpressing mutant FUS, which will al-
ter RNA processing due to FUS autoregulation. We
and others have recently created knockin models
that overcome the overexpression problem, and have
generated high depth RNA-sequencing on FUS mu-
tants in parallel to FUS knockout, allowing us to com-
pare mutation-induced changes to genuine loss of
function. We find that FUS-ALS mutations induce a
widespread loss of function on expression and splic-
ing. Specifically, we find that mutant FUS directly al-
ters intron retention levels in RNA-binding proteins.
Moreover, we identify an intron retention event in FUS
itself that is associated with its autoregulation. Al-
tered FUS levels have been linked to disease, and
we show here that this novel autoregulation mecha-
nism is altered by FUS mutations. Crucially, we also
observe this phenomenon in other genetic forms of
ALS, including those caused by TDP-43, VCP and
SOD1 mutations, supporting the concept that multi-
ple ALS genes interact in a regulatory network.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a relentlessly pro-
gressive neurodegenerative disorder characterized by loss
of motor neurons, leading to muscle paralysis and death
(1). About 5–10% of cases are inherited in an autosomal
dominant fashion (1). Numerous genes have been identified
as disease-causative, and have been central to the under-
standing of pathogenesis. RNA-binding proteins (RBPs),
most prominently TDP-43 and FUS, have been identified
as a major category of causative genes in familial ALS
(2,3). Both TDP-43 and FUS have multiple roles in RNA
metabolism, including transcription, splicing, polyadeny-
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lation, miRNA processing and RNA transport (4–9). Al-
though both proteins are predominantly localized to the nu-
cleus, in post-mortem brain tissue from mutation carriers
a mislocalization of the affected protein to the cytoplasm
can be observed. This shared pathology has suggested both
a nuclear loss of function and a cytoplasmic gain of toxic
function that play a role in familial FUS and TDP-43 ALS
(9). Although many studies have investigated the physiolog-
ical functions of FUS and TDP-43 through knockout and
overexpression experiments (10–23), the effect of disease-
causing mutations on RNA splicing has been more chal-
lenging to investigate. Due to the fact that both proteins
are very sensitive to dosage changes and very tightly reg-
ulated (24,25), mutation overexpression models are unfit to
address these questions.
We and others have used mice carrying mutations in the
endogenous Tardbp gene to show that TDP-43 mutations
induce a splicing gain of function (26,27). Here, we use our
novel knockin mouse model of FUS-ALS, FUS-14 (28),
in combination with data from other physiological mouse
and cellular models of FUS-ALS, to address the impact
of ALS-causing FUS mutations on RNA metabolism, and
splicing in particular. Although mutations have been ob-
served throughout the FUS gene, the most aggressive FUS
ALS-causing mutations cluster in the C-terminal region of
the protein, where the nuclear localization signal (NLS) re-
sides (Figure 1A) (29). These mutations affect the binding
of the nuclear localization signal by the nuclear import re-
ceptor Transportin (TNPO1) and induce an increase in cy-
toplasmic localization of the protein (29,30).
We find that FUS NLS mutations induce a splicing loss
of function, particularly in intron retention events. These
events are enriched in transcripts encoding RBPs, including
FUS itself. We propose intron retention to be a mechanism
whereby FUS autoregulates its own expression levels. Fi-
nally, we show that this regulatory splicing event is altered in
different ALS model systems. These findings shed light on
primary changes caused by ALS mutations, on how RBPs
act as a network to regulate each other, and on the diverse
mechanisms of RBP autoregulation. This is of central im-
portance for understanding the vicious cycle of cytoplasmic
accumulation of RBPs driving further RBP overexpression
and mislocalization that ensues in disease (31) and is a tar-
get for therapeutic strategies.
MATERIALS AND METHODS
External datasets
FUS-NLS and FUS KO mouse brain samples with their
respective controls (32) were downloaded from SRA ac-
cession SRP070906. FUS P517L mutants, FUS KO and
shared control samples from mouse motor neurons (33)
were downloaded from SRA accession SRP111475. Data
from a series of motor neuron differentiation experiments,
where induced pluripotent stem cells with and without VCP
mutations were differentiated to mature motor neurons
with RNA-seq libraries created from cells taken at 0, 7, 14,
21 and 35 days following differentiation (34), were down-
loaded from the Gene Expression Omnibus with accession
GSE98290. Stem cell-derived human motor neurons car-
rying SOD1 A4V mutations and their isogenic controls
(35) were downloaded fromGSE54409. FUS, U2AF65 and
TDP-43 mouse iCLIP (6) clusters were downloaded from
http://icount.biolab.si/. TDP-43, FUS, EWSR1 and TAF15
CLIP data from human and mouse were downloaded from
POSTAR (36). When the same CLIP sample had been pro-
cessed with more than one peak caller, the Piranha caller
was selected for presentation. Post-mortem human brain
RNA-seq from Frontotemporal Dementia with TDP-43 or
Tau pathology (37) was downloaded fromGSE90696. Post-
mortem human brain RNA-seq from sporadic and C9orf72
ALS patients (38) was downloaded from GSE67196.
Mouse lines
FUS-14 mice (B6N;B6J-Fustm1Emcf/H) were previously
described (28). FUS knockout mice were obtained from
the Mouse Knockout Project (Fustm1(KOMP)Vlcg). All
mouse lines were backcrossed onto C57BL/6J animals for
more than five generations. All procedures for the care and
treatment of animals were in accordance with the Animals
(Scientific Procedures) Act 1986 Amendment Regulations
2012.
RNA sequencing
For RNA sequencing experiments FUS-14 or KO het-
erozygous and homozygous mice were compared to their
respective wild-type littermates. Spinal cords were collected
fromE17.5mouse embryos. Tissues were snap frozen, geno-
typed and total RNA was extracted from the appropriate
samples using Qiazol followed by the mini RNAeasy kit
(Qiagen). RNA samples used for sequencing all had RIN
values of 9.9 or 10. cDNA libraries were made at the Ox-
ford Genomics facility using a TruSeq stranded total RNA
RiboZero protocol (Illumina). Libraries were sequenced on
an Illumina HiSeq to generate paired end 150 bp reads.
RNA-seq data processing
Mouse data were aligned to the mm10 build of the mouse
genome and human data aligned to the hg38 build of the
human genome using STAR (v2.4.2). Prior to differential
expression analysis, reads were counted across genes with
HTSeq. All code for exploratory data analysis, statistical
testing and visualization were carried out in the R statistical
programming language, using the tidyverse suite of pack-
ages. Data visualization and figure creation were aided by
the patchwork, stargazer, ggbeeswarm and ggrepel pack-
ages. All R code written for the project is publicly available
as interactive Rmarkdown notebooks (https://github.com/
jackhump/FUS intron retention).
Joint modeling of differential expression
Each dataset consists of FUS knockout samples, FUS NLS
mutation samples and wild-type controls. In the Bozzoni
dataset, the controls are shared but in the other two datasets
the knockout andmutation samples have their own separate
controls for use in two-way comparisons. Differential gene
expression was tested with DESeq2. Initially each compar-
ison (wild-type versus knockout or wild-type versus muta-
tion) was performed separately for each dataset, creating six
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Figure 1. Illustration of the models and mutations used in this study. (A) Transcript and protein structure of FUS. The major transcript encoding the
FUS protein in humans and mice is comprised of 15 exons. FUS protein contains a low complexity domain (LCD), an RNA recognition motif (RRM)
domain, two Arginine-Glycine-Glycine (RGG) domains, a zinc finger domain (Znf) and a nuclear localization signal (NLS) (29). (B) The three mouse FUS
NLS mutations used in this study. The Bozzoni group knocked in a point mutation to create the FUS P517L line, a missense mutation equivalent to the
human ALS P525L mutation. The Dupuis group created a FUS NLS line where the entire NLS is removed. We have used the FUS-14 mouse, where
a frameshift mutation leads to the skipping of exon 14 and a frameshifting of the remaining NLS sequence. (C) The FUS knockout alleles used by each
group. STOP here refers to the GeneTrap transgene used. (D) Schematic explaining the two joint models created from the six individual gene expression
datasets. (E) Proposed rationale for study. In wild-type cells FUS protein is predominantly nuclear but can shuttle to and from the cytoplasm. When FUS
is knocked out it will be reduced in both compartments but if the NLS is mutated or deleted then FUS will accumulate in the cytoplasm due to reduced
nuclear import.
individual analyses. To boost power and create a set of high
confidence changes, two joint models were created using ei-
ther the knockout (KO) or mutation (MUT) samples with
their specific controls. The joint model uses all the samples
of the same comparison together in a general linear model
with a dataset-specific covariate. DESeq2 uses a Bayesian
shrinkage strategy when estimating the log2 fold change.
For each gene the estimated log2 fold change is a combi-
nation of the three individual datasets. Genes are reported
as significantly differentially expressed at a false discovery
rate (FDR) threshold of 0.05 (39). For plots, gene expres-
sion values are raw counts multiplied by each sample’s size
factor generated by DESeq2. These normalized counts are
then normalized to the wild-type samples for each dataset
to visualize the relative change in expression.
To assess the level of overlap between the FUS KO and
FUS NLS joint models, two different overlap thresholds
were employed. The first, amore conservative threshold, de-
pends on a gene being significant at FDR < 0.05 in both
datasets. The second, more relaxed threshold, calls a gene
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as significant if it falls below FDR < 0.05 in one dataset
and has an uncorrected P-value < 0.05 in the other.
Joint modeling of splicing
SGSeq splicing analysis was performed on all the samples
together to discover and classify all potential splicing events
using the default parameters for finding both annotated
and novel splicing. Differential splicing for individual com-
parisons and joint models with a dataset-specific covariate
were performed using DEXSeq. The same overlap thresh-
old strategies were employed as for differential gene ex-
pression. SGSeq looks for all potential splicing events in
each sample and then counts the reads supporting either
the inclusion or exclusion of that splicing variant. Percent-
age Spliced In (PSI) values (40) for each splicing variant in
each sample were calculated by taking the read counts sup-
porting the inclusion event and dividing by the total reads
in that event.
Analysis of FUS splicing in other datasets
Details of other datasets used are contained in Supplemen-
tary Table S8. All datasets were processed using the same
pipeline as the FUS mouse data. SGSeq was used to quan-
tify and test FUS splicing.
Functional analysis of genes and splicing events
iCLIP data on FUS and U2AF65 from mouse brain (6)
were reprocessed by the iCOUNT iCLIP analysis pipeline
(http://icount.biolab.si/), and the set of FUS iCLIP clus-
ters that passed enrichment against background at FDR
< 0.05 were downloaded. Only iCLIP clusters with a min-
imum of two supporting reads were kept. Untranslated re-
gion (UTR) and coding exon (CDS) annotation were taken
fromGENCODEmouse (comprehensive; mouse v12). Any
intron retention, nonsense mediated decay or ‘cds end nf’
transcripts were removed. UTR coordinates were split into
5′ and 3′ UTR based on whether they overlapped an an-
notated polyadenylation site or signal (GENCODE mouse
v18 polyadenylation annotation). 3′ UTRs were extended
by 5 kilobases downstream to capture any unannotated se-
quence. Introns were defined as any gaps in the transcript
model between CDS and UTR coordinates. Promoter-
antisense coordinates were taken by flanking the 5′ UTR
sequence by 5 kb upstream and inverting the strand. Over-
laps between iCLIP clusters and genomic features were cre-
ated for each set of differentially expressed genes, split into
upregulated (log2 fold change > 0) or downregulated (log2
fold change < 0). Overlaps were done in a strand-specific
manner, with only iCLIP clusters in the same direction be-
ing used.
Whether an iCLIP cluster overlaps a genomic region de-
pends on both the affinity of the chosen protein for RNA
sequence of the motif and the abundance of the RNA in the
cell (41). In addition, a longer regionwould bemore likely to
overlap an iCLIP cluster by random chance than a shorter
region. When comparing sets of genomic regions, whether
genes or splicing events, this must be taken into account.
To test for enrichment of FUS iCLIP clusters in upregu-
lated and downregulated genes, each set of tested genes was
compared to a set of null genes with no evidence of differ-
ential expression (P > 0.05 in both models). The null set
was then restricted to genes with both length and expression
values that were within the first and third quartile of those
of the test gene set. The expression values were calculated
by taking the mean number of reads covering each gene in
the Fratta wild-type samples, with each sample read count
first normalized by the library size factor for each sample
calculated by DESeq2. The proportion of each set of genes
overlapping an iCLIP peak was then compared to that of
the null set with a  2 test of equal proportions.
For the splicing events found in the joint models, enrich-
ment tests were performed for different genomic features.
For these tests, the coordinates of the entire encompass-
ing intron were used for each splicing variant. Each test set
of splicing events was compared to a matched set of null
splicing events where P > 0.05 in both joint models. The
null events were chosen to have length and expression lev-
els within the first and third quartiles of that of the test set.
Proportions of overlap with iCLIP clusters between splicing
events and the null set were tested using a  2 test of equal
proportions. As a positive control in both analyses, the same
overlaps were computed with iCLIP clusters fromU2AF65,
also from (6).
Per nucleotide phyloP conservation scores (42) compar-
ing mouse (mm10) with 60 other vertebrates were down-
loaded from UCSC. The median phyloP score was calcu-
lated for each splicing variant and compared.
RT-PCR–intron retention validation
Primers were designed using Primer3 and in silico PCR
(UCSC). For both human and mouse FUS, the forward
primer was designed for exon 6 and the reverse primer de-
signed to span the spliced exon 8/9 junction to preferentially
amplify spliced FUS mRNA. An additional third primer
was designed to amplify a section of either intron 6 or in-
tron 7. Primer sequences are listed in Supplementary Tables
S5 and S6.
Cells were obtained from mouse spinal cord and/or
cultured mouse embryonic fibroblasts resuspended in Tri-
zol (Thermo Fisher Scientific). RNA was extracted using
miRNeasy Mini Kit (Qiagen) following the manufacturer’s
instructions. cDNA was obtained from extracted RNA
using SuperScript IV Reverse Transcriptase kit (Thermo
Fisher). Briefly, a mix was made of RNA template (500
ng for mouse brain; 100 ng for cultured cells (cyclohex-
imide treatment)), 10 mM dNTP, 50 mM oligo d(T)20, 50
mM random hexamer followed by 5 min of incubation at
65◦C and 1 min in ice. Mix was then complemented with
5X SuperScript IV Reverse Transcriptase buffer, 100 nM
DTT, RNase OUT and SuperScript IV Reverse Transcrip-
tase buffer followed by incubation at 23, 55 and 80◦C, 10
min each.
RT-PCR was carried out using 10X AccuPrime Taq
DNA polymerase mastermix system (Invitrogen). Each
PCR reaction mix contained 5 ng of gDNA, 10 mM of for-
ward and reverse primers. cDNAwas amplified with the fol-
lowing conditions: Intron 6 retention: One cycle of 5 min at
95◦C, followed by 30 cycles of 30 s at 95◦C, 30 s at 56◦C and
30 s at 68◦C, and finishing with 5 min incubation at 68◦C.
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Intron 7 retention: One cycle of 5 min at 95◦C, followed by
30 cycles of 30 s at 95◦C, 30 s at 61◦C and 30 s at 68◦C,
and finishing with 5 min incubation at 68◦C. Srsf7 NMD
positive control: One cycle of 5 min at 95◦C, followed by 35
cycles of 30 s at 95◦C, 30 s at 58◦C and 15 s at 68◦C, and
finishing with 5 min incubation at 68◦C. Amplified prod-
ucts were finally visualized using Agilent 4200 TapeStation
System following the manufacturer’s instructions. Results
were analyzed on TapeStation analysis software (Agilent).
Intron retention events are plotted as the percentage of the
total integrated area corresponding to the intron retention
product. One- or two-way ANOVA designs were employed
with pairwise t-tests with Holm correction for multiple test-
ing. For the RT-PCR on human fibroblasts, four technical
replicates were obtained from two independent cell culture
experiments, performed at different time points and derived
from the same original two human samples (referred as +/+
and G496Gfs/+).
Nuclear–cytoplasmic fractionation
Nuclear and cytoplasmic fractions were obtained from
DIV7 murine primary ventral horn cultures cultured from
WT E12-14 embryos. Briefly, the cells were washed with
PBS then treated with Accutase (Innovative Cell Technolo-
gies) and TrypLE Express (Thermo Fisher) consecutively
for 5 min each before lysis in Nuclei EZ lysis buffer (Sigma)
for 5 min on ice. The lysates were then centrifuged at 500
g for 5 min and the supernatant was extracted and saved
as the cytoplasmic fraction. The nuclear pellet was resus-
pended by gently triturating 5–8 times in freshly prepared
Nuclei EZ lysis buffer before centrifugation again at 500
g for 5 min. The supernatant was discarded, and the nu-
clear pellet was resuspended in RIPA buffer for 5 min on
ice. Nuclear DNAwas sheared by passing the nuclear lysate
through a 25 gauge needle 8–10 times. The nuclear and cy-
toplasmic lysates were then centrifuged again at 13 000 g
for 5 min. The supernatants were added to an appropri-
ate volume of TRIzol LS (Thermo Fisher) for RNA extrac-
tion. Equal amounts of RNAwere reverse transcribed using
IV VILO kit (Thermo Fisher) according to the manufac-
turer’s protocol. cDNA was used for end point PCR using
Go-Taq Polymerase (Promega). Bands were resolved on an
agarose gel and imaged using GelDoc (Bio-Rad). The same
3-primer design was used to amplify Fus with intron 6 or 7
retention. As a positive control, the nuclear RNA Xist was
amplified with primers from (43).
Xist nuclear RNA PCR: One cycle of 5 min at 95◦C, fol-
lowed by 30 cycles of 30 s at 95◦C, 30 s at 60◦C and 30 s
at 72◦C, and finishing with 5 min incubation at 72◦C. FUS
Introns 6 and 7 retention PCR: One cycle of 5 min at 95◦C,
followed by 30 cycles of 30 s at 95◦C, 30 s at 58◦C and 20 s
at 72◦C, and finishing with 5 min incubation at 72◦C.
Cycloheximide treatment
Mouse embryonic fibroblasts were treated with 100 g/ml
cycloheximide (Sigma) for 6 h before RNA was extracted
with Trizol (Thermo Fisher) and RT-PCR performed as
before. As a positive control, primers targeting the NMD-
sensitive exon 4 of Srsf7 were used from (44).
Plasmids
pLVX-EF1a-TS-EGFP-IRES-Puro was cloned by intro-
ducing an N-terminal Twin-Strep (TS)-tagged EGFP
cDNA (DNA String byGeneArt, Life Technologies) into
the EcoRI and BamHI sites of pLVX-EF1a-IRES-Puro
(Clontech, Cat. Nr. 631988). pLVX-EF1a-TS-OPT-FUS-
IRES-Puro was cloned by introducing an N-terminal Twin-
Strep (TS)-tagged codon optimized FUS cDNA (Gene syn-
thesis by GeneArt, Life Technologies) into the EcoRI and
BamHI sites of pLVX-EF1a-IRES-Puro (Clontech, Cat.
Nr. 631988).
Stable cell line generation
293T cells were cultured in DMEM/F12 supplemented
with 10% heat-inactivated, tetracycline-free fetal calf
serum (FCS) (Contech, Cat. Nr. 631105), penicillin (100
IU/ml)/streptomycin (100 g/ml) (Amimed, Bioconcept
Cat. Nr. 4-01F00-H). One day prior to transfection, ap-
proximately 5 × 106 HEK293T cells were plated in 150
cm2 flasks. About 28 mg of the pLVX-EF1a vectors and
144 ml of the fourth generation Lenti-X HTX Packaging
Mix (Clontech, Cat. Nr. 631249) were transfected using
the Xfect transfection reagent (Clontech, Cat. Nr. 631317).
Twenty-four hours post transfection the medium was ex-
changed. About 48, 72 and 96 hours post transfection vi-
ral particle containing supernatants were harvested and fil-
tered through a 0.45 m PES syringe filter (Membrane So-
lutions, Cat. Nr. SFPES030045S) followed by a 6-fold con-
centration using Lenti-X-Concentrator (Clontech, Cat. Nr.
631232) according to the manufacturer’s instructions.
One day before transduction, 2 × 105 HeLa cells were
seeded into four wells of a six-well plate. The next day, the
cells were exposed to 1 ml concentrated viral supernatant
in a total volume of 2 ml DMEM+/+ supplemented with
10 g/ml Polybrene (Sigma Aldrich, Cat. Nr. 107689) to
increase lentiviral transduction efficiency. The following 2
days, the same procedure was carried out with virus from
the second and third harvest, respectively. Finally, the trans-
duced cells were expanded under constant puromycin selec-
tion at 2 g/ml.
Knockdown of UPF1 by siRNAs
Knockdown of UPF1 was carried out in three dif-
ferent HeLa cell lines: wild-type cells, cells contain-
ing stably integrated GFP reporter gene, and cells con-
taining stably integrated codon-optimized FUS reporter
gene. Knockdown was achieved using siRNAs for UPF1
(GAUGCAGUUCCGCUCCAUUdTdT) and scrambled
control sequence (AGGUAGUGUAAUCGCCUUGdTd
T, Microsynth, CH). In short, 2–3 × 105 cells were seeded
into the well of a six-well plate and transfected the follow-
ing day with 40 nM siRNAs using Lullaby (OZBiosciences)
according to the manufacturer’s protocol. After 48 h, cells
were re-transfected with 40 nM siRNAs and harvested 48
h after the second siRNA transfection. Until harvest, cells
were split to avoid overgrowth of the cell culture. The effi-
ciency of the knockdown was assessed by western blotting.
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RT-qPCR
RNAanalysis was performed according to (45). Briefly, har-
vested cells were lysed in Trizol reagent (Thermo Fisher)
and RNA was isolated according to standard protocol.
Prior to reverse transcription (RT), DNase treatment was
performed using Turbo DNA-free kit (Invitrogen) to avoid
any DNA contamination. cDNA was synthesized using
AffinityScript Multiple Temperature Reverse Transcriptase
(Agilent) and RT control samples (without addition of RT)
were included for each sample. The cDNA was measured
in triplicates by RT-qPCR (reaction volume 15 l) using
Rotor-Gene Q (Qiagen) and Brilliant III Ultra-Fast SYBR
Green qPCRMaster Mix (Agilent). Oligonucleotides (final
concentration 0.6 M) used in the qPCR measurements are
listed in Supplementary Table S7. Ct values were converted
to fold changes using the delta-delta-Ct method (46) in R.
RESULTS
Joint modeling identifies high confidence FUS gene expres-
sion and splicing targets
To identify transcriptional changes induced by ALS-
causing FUSmutations, we performed high depth RNA se-
quencing on spinal cords from FUS-14 mice, a recently
described knockin mouse line carrying a frameshift muta-
tion leading to a complete loss of the nuclear localisation
signal (NLS) (Figure 1A and B) (28). As homozygous FUS-
14mice are perinatally lethal, we harvested spinal cord tis-
sue from late-stage embryonic mice (E17.5). In order to di-
rectly compare mutation-induced changes to genuine FUS
loss of function, we performed similar experiments in par-
allel using FUS knockout (FUS KO) and littermate control
spinal cords at the same developmental time-point (Figure
1C). The FUS KO mutation consists of a ubiquitous dele-
tion from the start to the stop codon of the FUS gene that
delivers a complete ablation of FUS gene expression. We
refer to these samples in the manuscript as the ‘Fratta sam-
ples’.
To enhance the confidence of our analysis and iden-
tify changes relevant across FUS NLS mutations, we took
advantage of two publicly available mouse CNS datasets,
whereALS-causativemutations in the endogenousFus gene
were expressed homozygously, andwhere FUSKOwas used
in parallel. TheRNA-seq datasets (described in Supplemen-
tary Table S1A) were (i) E18.5 brains from FUS-NLS,
a model of the R495X mutation that removes the entire
NLS (47), along with a GeneTrap FUS-KO that results in a
strong knockdown (32), together referred to as the ‘Dupuis
samples’; and (ii) ES-derived motor neurons from mice ho-
mozygous for the FUS-P517L mutation, corresponding to
human P525L (48) that mutates the critical proline residue
of the NLS, paired with a FUS-KO (33), together referred
to as the ‘Bozzoni samples’. The FUS KO construct used
by the Bozzoni lab is a GeneTrap inserted into intron 12
(17), which leads to a partial FUS knockout (Supplemen-
tary Figure S1B).
After performing differential expression and differential
splicing analyses on each individual dataset, we combined
the three datasets and performed two joint analyses for the
KO and NLS mutation samples with their respective con-
trols (Figure 1D). Throughout the manuscript, we refer to
these two joint models as FUS KO and FUS NLS, respec-
tively. This approach identifies differentially expressed and
spliced genes that have a shared direction of effect between
the three FUS KO or FUS NLS datasets. Although the
three mutations all impair the NLS and subsequent nuclear
localization of FUS, some mutations also impact the RGG
protein domains upstream of the NLS, which may influ-
ence the results. However, using a joint model will priori-
tize shared effects on expression and splicing and reduce or
remove effects specific to each mutation.
FUS NLS mutations have a loss-of-function effect on gene
expression
The joint analysis of differential expression identified 2136
and 754 differentially expressed genes at a false discovery
rate (FDR) of 0.05 in FUS KO and FUS NLS, respec-
tively (Figure 2A). The joint analysis identified fewer genes
than the sum of all individual datasets, indicating that a
large number of genes called as significantly differentially
expressed in a single comparison cannot be replicated in the
others (Supplementary Table S2A). We then looked for evi-
dence of either a shared or divergent gene expression signal
between the FUSKOmodel and the FUSNLSmodel.With
a conservative threshold for overlap, where a gene must be
significant at FDR < 0.05 in both models, we found an
overlap of 425 shared genes between FUS KO and FUS
NLS, with 329 genes being classified as mutation-specific
and 1711 as knockout specific.More permissive overlap cri-
teria, where a gene overlaps if it reaches FDR < 0.05 in one
model and an uncorrected P < 0.05 in the other, increased
the overlap to 1318 genes, reducing the specific genes to 186
in the FUS NLS model, and 961 in KO (Figure 2A). Com-
paring the direction of changes found for the 1318 overlap-
ping genes between FUS KO and FUS NLS showed that
only seven genes are altered in opposing directions, con-
firming a loss-of-function effect of Fus mutations on gene
expression (Figure 2B and Supplementary Figure S1A). A
linearmodel fit between the fold changes of the two datasets
showed that the effect of FUS NLS on gene expression is
76% that of FUSKO (β = 0.76;P< 1e-16 F-test;R2 = 0.90)
indicating that the magnitude of change is greater in FUS
KO than FUS NLS. The relative weakness of NLS muta-
tions compared to knockouts can be explained as NLS mu-
tant and FUS can still be detected in the nucleus, although
at lower amounts (28,49).
FUS NLS mutations induce synaptic and RNA-binding gene
expression changes
Among the most changed genes are the other members of
the FET family of RNA-binding proteins to which Fus be-
longs, Taf15 (Supplementary Figure S1C) and Ewsr1. In
addition we observed strong changes in Trove2, which is
downregulated in FUS NLS only and unchanged in FUS
KO (Supplementary Figure S1D).
Gene ontology (GO) analyses showed that genes com-
monly upregulated in bothFUSKOandFUSNLS to be en-
riched in RNAbinding, splicing andmetabolism terms, and
commonly downregulated genes in synaptic and neuronal
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Figure 2. FUS NLS mutations induce a loss of function on expression, with upregulation of RBPs and downregulation of neuronal genes. (A) Schematic
of the strict and relaxed thresholds for overlapping differentially expressed genes between the two joint models of FUS KO and FUS NLS. (B) Plotting the
log2 fold change for the NLS model against the joint KO model for the overlapping genes only. (C) Gene Ontology terms enriched in the three categories
of genes split by direction of change.
terms (Figure 2C). knockout-specific and mutation-specific
genes were less clearly enriched in specific functions (Figure
2C).
To investigate the relationship between FUS binding and
differential expression, we used a FUS iCLIP dataset from
embryonic day 18 mouse brain (6). We compared differen-
tially expressed genes to a non-differentially expressed set
of genes matched for length and expression levels and com-
pared the proportion of genes in the set bound either by
FUS or as a negative control, the splicing factor U2AF65
that should bind to all genes. We found enrichment of FUS
binding specifically within downregulated genes.When split
into genomic features, we observed this effect to be driven
by binding within introns (Supplementary Figure S2).
FUS NLS mutations induce a splicing loss of function
Weused the jointmodeling approach to assess the impact of
FUS NLS mutations and FUS KO on alternative splicing,
including both novel and annotated splicing isoforms. The
two joint models found 890 and 93 significant differential
splicing events at FDR < 0.05 in FUS KO and FUS NLS
(Figure 3A). The joint analysis increased power of detec-
tion of splicing changes for both FUS NLS and FUS KO,
and identified more events than the sum of the individual
analyses (Supplementary Table S2B).
Comparing the joint FUS KO and FUS NLS splicing
models, there were 405 overlapping events at the permis-
sive significance threshold used before, with 501 KO spe-
cific splicing events and only 16 FUS NLS-specific splic-
ing events (Figure 3A). There were no overlapping splicing
events that change in opposing directions, confirming FUS
mutations have a loss-of-function effect on splicing. Fur-
thermore, larger fold changes were present in the FUS KO
compared to FUS NLS joint models (β = 0.7, P < 1e-16;
F-test; R2 = 0.89), supporting the reduced nuclear localiza-
tion of the mutant FUS as the main responsible factor for
the loss of splicing function.
We then examined sequencing data from heterozygous
FUS KO and FUS-14 samples to investigate whether
splicing changes had a gene dosage effect. Comparison
of splicing events between the heterozygous and homozy-
gous FUS-14 and FUSKO samples found 34 overlapping
FUS-14 events and 115 overlapping FUSKOevents (Sup-
plementary Figure S3A). Fold changes showed heterozy-
gotes to have a reduced effect size compared to the homozy-
gotes in both FUS-14 (β = 0.57; P= 1e-11) and FUSKO
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Figure 3. NLSmutant FUS induces a splicing loss of function. (A) Schematic of the strict and relaxed thresholds for overlapping differential splicing events
between the two joint models of FUS KO and FUS NLS. (B) Plotting the log2 fold change for the FUS NLS model against FUS KO for the overlapping
splicing events. (C) Counts of each category of splicing events found in the three sets. (D) The proportion of each type of splicing variant in each category
that overlap a FUS iCLIP cluster. Background sets of non-regulated splicing events matched for length and wild-type expression are represented by dotted
lines. P-values from  2 test, corrected for multiple testing with the Bonferroni method.
(β = 0.67; P < 1e-16), thus demonstrating a gene dosage
effect on splicing.
Intron retention is the most common splicing change induced
by FUS mutations
Separating splicing events by type showed a similar distri-
bution between KO-specific and events found in both FUS
KO and FUSNLSmutations (‘overlapping events’) as both
were dominated by retained introns and complex events
(Figure 3C). The latter are difficult to interpret as multiple
types of alternative splicing co-occur within the same locus.
This can be seen in Ybx1, where a retained intron is accom-
panied by an alternate cassette exon and the splicing of both
were altered in both FUS KO and FUS NLS (Supplemen-
tary Figure S3B and C). Cassette exons and alternate 5′ and
3′ splice sites were found in all three sets of genes, with alter-
nate 5′ sites appearing at twice the rate of alternate 3′ splice
sites. FUS has been shown to interact with the U1 snRNP,
which may explain this over-representation (50,51).
In vivo and in vitro studies of RNA–protein interaction
have proposed direct regulation of splicing by FUS through
binding to introns (5–8). We used published FUS iCLIP
clusters (6) to show that retained introns are strongly en-
riched for FUS-binding sites, with the strongest enrich-
ment present for the overlapping retained introns (P= 4.4e-
22;  2 test; Figure 3D). A small but significant enrich-
ment in TDP-43 binding was seen in the same set of events
(P = 0.027; Supplementary Figure S3D), with no enrich-
ment in U2AF65 binding. Surprisingly, no enrichment of
FUSbindingwas observed in cassette exons, suggesting that
these events may not be the direct result of altered FUS ex-
pression.
We and others have previously shown that knocking out
or knocking down TDP-43 in humans and mice leads to
the inclusion of novel exons (so-called ‘cryptic splicing’)
(52,53). We then demonstrated that missense mutations in
the low-complexity domain of TDP-43 cause the skipping
of constitutive included exons, a phenomenon we termed
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‘skiptic splicing’ (26). We applied our previously used cri-
teria to classify the cassette exons found to be mis-spliced
upon FUS NLS mutation or knockout by their percent
spliced in (PSI) values. No exons were classified as skiptic or
cryptic, in line with our previously found absence of novel
splicing in FUS knockdown data (53).
FUS-regulated retained introns are enriched in RBP-
encoding transcripts and are highly conserved
Gene ontology analysis for each category of events showed
a clear enrichment in RNAbinding and neuronal GO terms
in the overlapping splicing events. Specifically, genes with
retained introns were often related to RNA binding (Fig-
ure 4A). These transcripts include the U1 splicing fac-
tor Snrnp70, the FET protein family members Ewsr1 and
Taf15, and Fus itself. Conversely, neuronal GO terms were
only enriched in cassette exons.
RBPs often contain intronic sequences that are very
highly conserved (54) and have been proposed to be impor-
tant for their post-transcriptional regulation (55). To test
whether the splicing events with confirmed FUS binding
show high sequence conservation, we calculated the median
phyloP score using the 60-way comparison between mouse
and other species for each encompassing intron (42). Sets of
events were then tested on the proportion of the set with a
median phyloP score>0.5, where a score of 0 is neutral and
>1 is highly conserved. Only retained introns were enriched
in sequence conservation, and to a greater extent for FUS
NLS and FUS KO overlapping (P = 1.2e-10) than FUS
KO-specific events (P = 0.048; Figure 4B). Thirty-five re-
tained intron events are found in genes with RBP-related
GO terms. Notably, the direction of change shows these
introns to be predominantly decreasing in retention upon
FUS KO or NLS mutation. In addition, 20 out of 35 events
have a FUS binding iCLIP cluster within 1 kb of the intron
region (Figure 4C).
Taken together, these results show that nuclear depletion
of FUS through either knockout or NLS mutation leads to
a set of splicing changes enriched in conserved intron reten-
tion events predominantly affecting RNA-binding proteins.
Conversely, cassette exons are not bound by FUS beyond
random chance and are flanked by non-conserved introns.
Modest overlap between differentially expressed and differ-
entially spliced genes
To test whether genes differentially expressed under FUS
mutation or knockout are also differentially spliced, we in-
tersected lists of genes from each type of splicing event with
the set of 1318 differentially expressed genes in the permis-
sive overlap group. About 18 of 163 genes with at least one
complex splicing event were also differentially expressed (P
= 9.5e-6, Fisher’s exact test), as were 10 of the 83 genes with
retained introns (P = 1.2e-3) (Supplementary Table S3A).
Neither splicing event type had a bias toward up- or down-
regulation of expression. Thirty genes in total were both dif-
ferentially expressed and spliced, including the FET family
members Taf15 and Ewsr1, as well as fellow RNA-binding
proteins Srsf6 and Rbmx (Supplementary Table S3B). As
the majority of differentially spliced genes were not differ-
entially expressed and vice versa, FUS appears to have pre-
dominantly separate roles in gene expression and splicing.
FUS autoregulates through highly conserved retained introns
The joint splicing analyses found two retained introns (in-
trons 6 and 7) in the Fus transcript to be less retained
in FUS NLS mutants. Both introns are highly conserved
acrossmammalian species and containmultiple FUS iCLIP
peaks in both mouse and human (Figure 5A). As retention
of these introns decreased in the presence of FUSmutations,
we hypothesized that their retention could have a regula-
tory function on FUS expression. Numerous RBPs regu-
late their expression by binding their own transcript (24,56–
58) so that when protein levels are high, increased bind-
ing of the pre-mRNA shifts alternative splicing toward the
production of an untranslated isoform, either degraded by
nonsense-mediated mRNA decay (NMD) or by detaining
the transcript in the nucleus to avoid translation in the cy-
toplasm (59–62). The FUS intron 6/7 region is the putative
locus of FUS autoregulation through the skipping of exon
7 that causes a frameshift, producing an NMD-sensitive
transcript (25). However, when examining RNA-seq junc-
tion coverage of the FUS gene in all our mouse datasets, we
failed to observe skipping of exon 7 in any sample (Figure
5B). Instead, the retention of both introns 6 and 7 decreased
in the presence of FUS mutations in all three datasets, de-
spite the baseline level of intron retention in wild-type sam-
ples being highly variable between datasets. Heterozygous
FUS-14mice also showed a significant reduction in intron
retention, albeit less than the homozygotes, demonstrating
a dose-dependent response. We validated our findings us-
ing RT-PCR and confirmed that intron retention decreases
in a mutation dose-dependent manner (Figure 5C; intron 6
P = 5.1e-4; intron 7 P = 8.5e-3; ANOVA; Supplementary
Figure S4). We failed to detect a band corresponding to the
skipping of exon 7 in any sample.
FUS autoregulation is conserved in human cells
We then tested whether the same phenomenon of reduced
intron retention occurs in human cells, and used primary
fibroblasts from a patient carrying the ALS-causative het-
erozygous FUS mutation G496Gfs that induces a strong
cytoplasmic FUS mislocalization through a frameshift that
removes the NLS (28). RT-PCR showed a decrease in both
introns 6 and 7 retention relative to a FUS wild-type hu-
man sample (Figure 5D; intron 6 P = 0.001; intron 7 P =
0.08; ANOVA; Supplementary Figure S5). These changes
were smaller than those observed in homozygous mice, and
more similar to the heterozygous mice. As with the mouse
samples, no change in exon 7 splicing was observed.
FUS intron 6/7 retention determines transcript nuclear de-
tention
As retained intron transcripts can accumulate in the nu-
cleus (62), we performed cellular fractionation on wild-type
mouse ventral horn spinal cord cultures and performedRT-
PCR to assess the level of retention of introns 6 and 7 in
the nucleus and cytoplasm. We observed retention of either
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Figure 4. FUS modulates the inclusion of a set of highly conserved RNA-binding protein introns. (A) Significantly enriched Gene Ontology terms found
in genes split by category and splicing variant type. (B) The proportion of each type of splicing event that has a median phyloP conservation score >0.5.
Background sets as before. P-values from a  2 test, corrected for multiple testing with the Bonferroni method. (C) All intron retention events found in
the overlapping set found to have an RNA-binding GO term, along with the two FUS introns that are mutation specific. PSI values were calculated for
each individual splicing analysis and presented from negative (blue) to positive (red). Events not identifiable in a dataset are colored gray. Median phyloP
conservation across each intron coded from 0 (non-conserved; white) to 1.5 (highly conserved; black). Additionally, each intron is noted for the presence
of FUS iCLIP cluster overlapping (black) or within 1 kb of either end of the intron (dark gray).
intron only in the nuclear fraction (Figure 5E and Supple-
mentary Figure S6). These data are in agreement with a re-
cent study using the APEX-seq method to label RNA in
different cellular compartments (63), which found FUS in-
trons 6 and 7 to be enriched in the nucleus in human cells.
FUS introns 6/7 also contain numerous premature stop
codons suggesting they may undergo nonsense-mediated
decay (NMD), which may explain the absence of intron re-
tention transcripts in the cytoplasm. In order to understand
whether FUS intron-retention transcripts are degraded in
the cytoplasm or are instead detained in the nucleus, we
tested their sensitivity to NMD. Following incubation with
cycloheximide (CHX) to inhibit translation and therefore
blockNMD (64), we observed no change in intron retention
in either wild-type or FUS-14 homozygous cells (Figure
5F), despite observing a robust inhibition of NMD when
looking at a known event in Srsf7 (Supplementary Fig-
ure S7). Similar results were obtained in human cells when
UPF1, an essential NMD factor, was knocked down using
siRNA (Figure 5G and Supplementary Figure S8), showing
only a modest effect on FUS mRNA levels.
In order to further validate FUS autoregulation, we in-
vestigated the effect of FUS overexpression. FUS overex-
pression has previously been shown to downregulate en-
dogenous Fus transcripts (20,25,65). However, the presence
of an overexpression plasmid makes it difficult to evaluate
the expression of endogenous FUS. To circumvent this, we
generated stably transduced HeLa cell lines that constitu-
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Figure 5. FUS autoregulation occurs through the modulation of an intron retention event leading to transcript nuclear detention. (A) FUS introns 6
and 7 are highly conserved and have multiple FUS iCLIP binding peaks. Retention of introns 6 and 7 decreases with increasing dose of FUS-14.
RNA-seq coverage for wild-type, FUS-14 heterozygous and FUS-14 homozygous samples are accompanied by FUS iCLIP (Rogelj et al., 2012) and
phyloP conservation (60 way) tracks. (B) Percentage spliced in (PSI) values of intron 6, intron 7 and exon 7 in the three datasets, including the FUS-14
heterozygotes. (C) RT-PCR validation of the reduction in introns 6 and 7 inclusion with increasing dose of FUS-14 mutation. Left panel: FUS intron
6; ANOVA genotype P = 5.1e-4. Right panel: FUS intron 7; ANOVA genotype P = 8.5e-3. Pairwise t-tests reported on plot, corrected by Holm method.
(D) RT-PCR validation of reduced retention of FUS introns 6 and 7 in fibroblasts from a human patient with a FUS G496Gfs mutation (n= 1) compared
to a healthy control (n = 1). RT-PCR repeated in triplicate for each sample. ANOVA genotype P = 0.001; intron 7 ANOVA genotype P = 0.08 (E) RT-
PCR on FUS introns 6 and 7 on nuclear and cytoplasmic RNA fractions. Intron 6 t-test P = 0.025; Intron 7 t-test P = 0.1. (F) Translation blocked with
cycloheximide (CHX) to observe whether the intron retention transcript is sensitive to nonsense-mediated decay. Left panel: FUS intron 6 retention is not
altered with CHX treatment. ANOVA treatment P = 0.96; genotype P = 5.7e-5; interaction P = 0.86. Right panel: FUS intron 7 retention is unchanged
by CHX treatment. ANOVA treatment P = 0.10; genotype P = 7.9e-6; interaction P = 0.1. Pairwise t-tests reported on plot, corrected by Holm method.
(G) Reduced endogenous FUSRNA levels in HeLa cells expressing codon-optimized FUS compared to HeLa cells expressing a GFP control, as measured
by qPCR. This reduction was mostly unaffected by the siRNA depletion of UPF1.
tively overexpress FUS cDNA using alternative codons, al-
lowing us to design qPCR primers that selectively amplify
endogenous FUS, but not the overexpressed version. We
investigated the effects of FUS overexpression on endoge-
nous FUS expression using qPCR. As expected, FUS over-
expressing cells showed a strong downregulation of endoge-
nous FUSmRNA compared to cells expressing a GFP con-
struct (Exons 1–3 P< 1e-16; Exons 6–9 P= 1e-7; ANOVA;
Figure 5G).
Taken together, these experiments show that FUS intron
retention is NMD-insensitive. We therefore suggest that
FUS regulates its own expression through the retention of
introns 6 and 7. This transcript is detained in the nucleus, re-
ducing the amount of cytoplasmic FUS available for trans-
lation (Figure 7).
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FUS intron retention is co-regulated by TDP-43 and altered
in other ALS models
FUS shares RNA targets with another ALS-associated
RNA-binding protein, TDP-43 (5). Despite FUS iCLIP
peaks being present throughout the Tardbp gene, neither
FUS knockout nor NLS mutation altered Tardbp expres-
sion or splicing.
However, using TDP-43 CLIP data from human and
mouse collected by the POSTAR database (36), we identi-
fied a conserved TDP-43 binding site within FUS intron 7,
∼400 nucleotides downstream of the 5′ splice site in a UG-
rich region conserved between mouse and humans (Figure
6A and B). UG dinucleotides are the known binding mo-
tif of TDP-43 (66). To test whether TDP-43 is also involved
in regulating the retention of FUS introns 6 and 7, we re-
analyzed RNA-seq data where TDP-43 was knocked down
in adult mice with an antisense oligonucleotide (4) as well
as adult mice homozygous for a C-terminal TDP-43 mu-
tation (M323K) that we previously showed to cause a gain
of splicing function (26). TDP-43 knockdown caused a re-
duction in FUS intron retention, similar to FUS NLS mu-
tations (Figure 6C). Conversely, TDP-43 M323K mice had
an increase in FUS intron retention relative towild-type.We
observed no changes in FUS intron retention in embryonic
mice homozygous for a splicing-null mutation (F210I) (26),
suggesting a developmental component to TDP-43 cross-
regulation of FUS. FUS introns 6 and 7 are also bound by
fellow FET family members TAF15 and EWSR1 in human
and mouse (Supplementary Figure S9).
A previous study differentiated human motor neurons
from induced pluripotent stem cells (iPSC) with and with-
out mutations in VCP, an ALS-causative gene that induces
TDP-43 pathology (34,67). The authors observed a set of
retained intron events that change earlier in differentiation
in the VCP mutant cells compared to the wild-type. These
changes occurred primarily in RBPs, suggesting a pertur-
bation in splicing factor networks during development. To
compare the FUS-regulated murine splicing events with
those found in VCP mutant human cells, we overlapped the
143 human genes found to have intron retention events with
the set of 219 mouse genes with either intron retention or
complex events in both FUS NLS and FUS KO and found
an overlap of 12 genes (P = 1e-5, Fisher’s exact test; Sup-
plementary Table S4). Remarkably, this included FUS itself.
Re-analysis of published RNA-seq data from (34) demon-
strated that the retention of FUS introns 6 and 7 is increased
specifically in the transition between iPSC and neural pre-
cursor cell (NPC) stage in theVCPmutants (Supplementary
Figure S10A).NeitherFUS norTARDBPwas differentially
expressed at any stage (Supplementary Figure S11).
The same study also found intron retention changes in
another ALSmodel, SOD1A4Vmutations in iPSC-derived
motor neurons (35). Re-analysis of the same RNA sequenc-
ing data showed a robust increase in FUS intron retention
in the presence of SOD1 mutations (Supplementary Figure
S10B). Again, neither FUS nor TARDBP was found to be
differentially expressed in this dataset (Supplementary Fig-
ure S11).
At last, we asked whether FUS intron retention was al-
tered in human patients with ALS or FTD. We re-analysed
two human post-mortem brain datasets: one from FTD
patients with either Tau (FTD-Tau) or TDP-43 (FTD-
TDP) pathology (37) and the second from ALS patients
with either C9orf72 mutations (c9ALS) or without known
mutations (sALS) where both groups should have TDP-
43 pathology (38). Both datasets sampled frontal cor-
tex and cerebellum tissue from patients along with non-
neurological disease controls. The cerebellum does not ex-
hibit any TDP-43 pathology in either disease (68). There-
fore, any TDP-43-related splicing changes should be re-
stricted to the frontal cortex. These two datasets allow us
to test whether FUS intron retention changes occur only in
patients and tissues that had pathological TDP-43mislocal-
ization.
The two datasets had very different overall levels of FUS
intron retention with ∼75% retention of both FUS introns
in the FTD dataset but levels closer to 20% in the ALS
dataset (Supplementary Figure S12), despite the two RNA-
seq datasets being prepared similarly (Supplementary Table
S8). No significant difference in intron retention levels or in
exon 7 skipping between disease and control was observed
in either dataset. As TDP-43 mislocalization occurs only in
a minority of cells, a larger sample size or a cell-type spe-
cific assay may be needed to reveal changes in FUS splicing
in post-mortem human brain samples.
Taken all together, these findings suggest that FUS regu-
lation may be altered in the presence of ALS-causative mu-
tations in other genes.
DISCUSSION
FUS is a central player in ALS biology and its role in RNA
metabolism has been intensively studied, but how disease-
causing mutations impact upon RNA processing is still be-
ing determined. One limitation has been that FUS, like
many other RBPs, is extremely sensitive to gene dosage.
Therefore, commonly used models, where mutant FUS is
overexpressed, cannot disentangle the effects of overexpres-
sion from those of the mutation. We and others have gener-
ated FUS-ALS models where mutations were inserted into
the endogenous gene to observe the impact on gene ex-
pression and splicing. In order to specifically investigate
splicing changes, we generated high depth sequencing data
from spinal cords of our mutant FUS mice, alongside FUS
knockout samples, to compare mutant-induced changes to
a pure loss of function. In order to identify with high con-
fidence changes relevant to multiple FUS-ALS models we
performed a joint analysis, combining our data with other
publicly available datasets where endogenousFusmutations
had been studied in parallel to samples from knockout tis-
sue. The sequencing conditions differed between datasets
(Supplementary Table S1B), with some more suited for ex-
pression analysis rather than for splicing analysis. Nonethe-
less, the joint analysis model proved to be extremely power-
ful and allowed us to identifymore splicing changes than us-
ing any single dataset independently. Furthermore, this ap-
proach limits artifactual findings from individual datasets
and allowed us to define a comprehensive high-confidence
list of both expression and splicing targets induced by ALS-
FUS mutations and FUS loss.
The comparisons between the joint analysis of FUSNLS
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Figure 6. TDP-43 co-regulates FUS intron retention. (A) Mouse TDP-43 cross-linking and immunoprecipitation (CLIP) data overlap a TG-rich section of
Fus intron 7. (B) Human TDP-43 CLIP data overlap within FUS intron 7 in a section rich with TG sequence. (C) RNA-seq traces of representative samples
demonstrate decreased Fus intron retention in TDP-43 knockdown and increased retention in TDP-43 M323K mutation, both in adult mouse brain. No
effect is seen with the RNA-binding mutant F210I in embryonic mouse brain. Y-axis of each trace refers to the maximum read depth. (D) Percentage
spliced in quantification from each TDP-43 dataset of introns 6 and 7 retention. P-values are presented from splicing analysis on each dataset.
mutations and FUS knockout show that FUS mutations
have a loss-of-function effect both on expression and splic-
ing. This is a key difference from mutations in TDP-43, the
other major RBP implicated in ALS, where specific muta-
tions lead to gain of splicing function (26,27). The fact that
the changes appear weaker in NLS mutations compared to
FUS knockout is compatible with mutant FUS still being
found at low levels in the nucleus of all the analyzed mu-
tants, and supports a dosage-dependent nuclear loss of nu-
clear function.
The high depth and relatively long reads (150 bp) of our
sequencing data allowed us to conduct an unbiased analy-
sis of splicing, which highlighted intron retention and com-
plex splicing events to be the most frequently altered class
of changes, whilst cassette exon events, which had been pre-
viously described by using a targeted approach (32), are less
abundant. Interestingly, whenwe assessed the association of
FUS binding to different splicing events using CLIP, FUS
was linked directly to intron retention, but not to cassette
exon splicing, suggesting the latter category could be due to
downstream or indirect effects.
Intriguingly, the FUS transcript features among the
strongest intron retention changes induced by FUS muta-
tions, with themutation inducing a reduction in retention of
introns 6 and 7. This led us to consider the possibility that
FUS intron 6/7 retention had a biological function. This
region has been previously suggested to be involved in FUS
autoregulation through alternative splicing of exon 7 (25),
but we were unable to observe this at significant levels in any
of the datasets we analyzed in both human and mouse. The
two introns are highly conserved across species, and FUS
iCLIP data showed widespread FUS binding across both
introns, supporting their retention as a putative autoregu-
latory mechanism.
Comparing nuclear and cytoplasmic fractions we found
that FUS intron 6/7 retention is preferentially localized to
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Figure 7. Schematic of proposed FUS autoregulationmechanism. Inwild-type cells, FUS protein shuttles between the nucleus and cytoplasm. FUS binding
within FUS introns 6 and 7 promotes their retention. The intron retention transcript is restricted to the nucleus, reducing the amount of cytoplasmic FUS
mRNA available for translation. In conditions of low FUS protein, intron retention will be reduced and cytoplasmic FUS transcript will be increased. In
contrast, in cells with FUS NLS mutations, mutant FUS is not transported to the nucleus as effectively. This reduces the ability of FUS protein to regulate
FUS mRNA production through intron retention. This could lead to a vicious cycle of ever-increasing FUS protein in the cytoplasm, which may have
toxic effects.
the nucleus (Figure 5E), and experiments in both human
andmouse cells found the retained intron transcripts, which
are predicted to undergo NMD, to be NMD-insensitive
(Figure 5F–G), suggesting they are not degraded in the
cytoplasm, but are instead detained in the nucleus. Nu-
clear detention is a recognized mechanism to control gene
expression (62) and has been described to be important
in the regulation mechanism of other RNA-binding pro-
teins through exosome-dependent nuclear RNA degrada-
tion (69). We therefore propose a new autoregulation mech-
anism for FUS, whereby the level of nuclear FUS protein is
buffered by its binding to the FUS mRNA. Increased nu-
clear FUS would increase the retention of FUS introns 6
and 7, leading to transcript nuclear detention and reduced
FUS protein levels in a negative feedback loop (Figure 7).
Transcripts with detained introns have been characterized
as either ‘reservoirs’ of RNA to be spliced at a later time or
‘dead ends’, where the transcript is subsequently degraded
(70). Further work will be needed to determine the fate of
the intron retained FUS transcript.
The discrepancy between our results and those of Zhou
et al. (25) could be explained by FUS autoregulation having
two independent mechanisms, using either detained introns
or NMD-sensitive exon skipping depending on the cell type
and developmental time-point. This would be analogous to
TDP-43, where both the nuclear retention of a long 3′ UTR
transcript as well as the production of an NMD-sensitive
transcript through 3′ UTR splicing have both been observed
(24,71). Further work could elucidate that autoregulatory
mechanism is favored in different cell types.
Genes changed both at the splicing and expression level
by Fus mutations are enriched in ‘RNA metabolism’ GO
terms, supporting a secondary effect on splicing of other
RBPs. Furthermore, the altered intron retention events are
specifically enriched for ‘RNA metabolism’ suggesting that
also a cross-regulation among RBPs may occur through
this mechanism, which is compatible with the growing ev-
idence of RBPs functioning as a sophisticated regulatory
network (60,72–74). This raises the question as to what
other proteins contribute to the regulation of FUS levels,
and whether other ALS-linked proteins could play a role.
FUS binds and regulates the levels and splicing of EWSR1
and TAF15, both associated with ALS through rare famil-
ial mutations (75,76) and both EWSR1 and TAF15 bind
to Fus introns 6/7 (Supplementary Figure S9). Although
FUS depletion leads to an upregulation of TAF15, reduc-
ing TAF15 has no effect on FUS expression (77). Intrigu-
ingly, we found TDP-43 to bind reproducibly to intron 7
in both human and mouse, and that in adult mice TDP-
43 knockdown induces a significant decrease in retention of
both introns, whilst the opposite was found in the presence
of gain-of-function TDP-43 mutations. No changes were
found in an embryonic dataset from mice where TDP-43
has a decreased RNA-binding capacity. This observation
could be due to different co-regulation patterns occurring
across developmental stages (78,79). Our findings support a
role for TDP-43 in regulating FUS through the same post-
transcriptional mechanism by which FUS regulates itself.
FUS intron retention is also altered in the presence of
both VCP and SOD1 mutations, two ALS-related genes
that are not RBPs but have recently been linked to alter-
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ations in intron retention (34). Of note, whilst VCP muta-
tions lead to typical TDP-43 pathology, SOD1mutant cases
do not show TDP-43 mislocalization, but rather cytoplas-
mic inclusions of misfolded SOD1. Our findings of FUS
regulation being altered in VCP and SOD1 cases do not
show a direct link between these proteins and FUS regu-
lation, but rather support FUS dysregulation being present
across awide range ofALS cases, in line with recent findings
(80). Future targeted studies could more sensitively assess
changes in FUS regulation across a variety of conditions.
Such studies could make use of a minigene incorporating
FUS introns 6 and 7.
Finally, we re-analyzed transcriptome data from human
post-mortem brain inALS andFTLD to test whether TDP-
43 pathology, seen in both diseases, would be reflected by
changes in FUS splicing. The fact we could not observe any
changes may be due to the high variability of post-mortem
disease brain tissue and the fact that TDP-43 mislocaliza-
tion occurs in a minority of cells, compared to more homo-
geneous cell lines or animal models. Larger cohorts of post-
mortem brains or experiments isolating cells with TDP-43
pathology such as (81) will be required to fully explore this
question.
In conclusion, we have found that FUSmutations induce
a loss of splicing function, particularly affecting intron re-
tention events in other RBPs. We show that an intron reten-
tion event in the FUS transcript is a mechanism for its au-
toregulation and is modified not only by mutations in FUS,
but also by ALS-causative mutations in TDP-43, VCP and
SOD1. Altered regulation of FUS can contribute to neu-
rotoxicity. Elucidating how this occurs and how other ALS
proteins play a role in this mechanism advances our under-
standing of the ALS pathogenic cascade.
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